TrialDoklady. Biochemistry and biophysics2026
The Efficacy and Safety of Divozilimab in Patient with Systemic Sclerosis: 48-Week Results of the Randomized Double-Blind Placebo-Controlled Phase III Clinical Study LIBERIUS.
L P Ananyeva et al.PubMed ↗Publisher ↗
No numbers read from the abstract.